Risk Factors Update Summary
- Net losses increased from $58.8 million to $76.4 million for the year ended December 31, 2022.
- Accumulated deficit rose from $210 million to $287.9 million as of December 31, 2023.
- Cash and cash equivalents, and marketable securities are expected to fund operations into 2026.
- Need to expand clinical operations, CMC, and regulatory capabilities for pivotal trials.
- Failure to develop additional product candidates may limit commercial opportunity.
- Use of SCS Microinjector for ocular oncology indications in the United States.
- Introduction of the California Privacy Rights Act of 2020 and potential impact on compliance.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1501796&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.